CURRICULUM VITAE Elizabeth Carloss Riley M.D., FACP James

CURRICULUM VITAE

Elizabeth Carloss Riley M.D., FACP

James Graham Brown Cancer Center

University of Louisville

529 S. Jackson Street

Louisville, KY 40202

[email protected]

502-562-4370

502-562-6811 (fax)

EDUCATION

1998 B.A. Duke University, Durham, NC (English)

2002 M.D. University of Louisville, Louisville, KY

2002-2003 Intern, Internal Medicine, Beth Israel Deaconess Medical Center, Harvard

Medical School, Boston MA

2003-2005 Resident, Internal Medicine, Beth Israel Deaconess Medical Center, Harvard

Medical School, Boston, MA

2005-2006 Fellow, Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard


2006-2007 Chief Resident, Internal Medicine, Beth Israel Deaconess Medical Center,

Harvard Medical School, Boston, MA

2007-2009 Fellow, Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard


ACADEMIC APPOINTMENTS

2002-2006 Clinical Fellow in Medicine

Harvard Medical School

Boston, MA

2006-2007 Instructor in Medicine


Boston, MA

2007-2009 Clinical Fellow in Medicine


Boston, MA

2009- present Assistant Professor of Medicine

Division of Medical Oncology/Hematology


Louisville, KY

2013-present Assistant Division Director

Division of Medical Oncology/Hematology


Louisville, KY

2013-present Director, Breast Multidisciplinary Clinic

James Graham Brown Cancer Center


Louisville, KY

mailto:[email protected]

Elizabeth Riley, M.D., FACP 7/25/14

Page 2 of 19

2

OTHER POSITIONS AND EMPLOYMENT

1997 ULCA School of Public Health, Los Angeles, CA

Analyzed community health indicators for Healthy People 2000.

1998 United States Senate, Washington, D.C.

Researched and prepared information relating to education and health care in Senator

Mitch McConnell’s office

2005-2006 Medical Staff

Department of Medicine

Division of Hematology/Oncology

Mount Auburn Hospital

Cambridge, MA

CERTIFICATION AND LICENSURE

2002 Massachusetts Medical License (# 220429)

2006 Diplomat, American Board of Internal Medicine (ABIM)

2009 Diplomat, ABIM, subspecialty Medical Oncology

2009 Diplomat, ABIM, subspecialty Hematology

2010 Kentucky Medical License (#43332)

PROFESSIONAL MEMBERSHIPS AND ACTIVITES

1998 Member, Kentucky Medical Association

1998 Member, American Medical Association

1999 Member, American College of Physicians

1999 President, Kentucky Medical Association Medical School Section, University of Louisville

2002-2010 Member, Massachusetts Medical Association

2003-2005 Resident Representative Massachusetts Council of Associates, American College of Physicians,

2005- Member, American Society of Clinical Oncology, member

2005- Member, American Society of Hematology

2006- 2009 Member, Clinical Practice Committee, American Society of Clinical Oncology

2010- Governing Council, American College of Physicians, Kentucky Chapter

2010- Nominating Committee, Greater Louisville Medical Society, Nominating Committee

2011- Member, Health Disparity Advisory Group (HDAG), American Society of Clinical Oncology

2011- Member, HDAG Quality subcommittee, American Society of Clinical Oncology

2011- Member, HDAG Public Policy subcommittee, American Society of Clinical Oncology

2011- Fellow, American College of Physicians

2013- Member, ASCO Health Disparities Quality Work Group

2014- Ad Hoc Reviewer, Journal of Oncology Practice

HONORS AND AWARDS

1994 Phi Eta Sigma Honor Society, Duke University, Durham, NC

1997 - 1998 Dean’s List, Duke University, Durham, NC


Page 3 of 19

3

1999 Finalist, Research! Louisville. University of Louisville. Louisville, KY: “Influence of Estrogen

Mimics on ERE Recognition by Human Estrogen Receptor- alpha.”

2000 Honorable Mention, Poster Session. Kentucky Medical Association Annual Meeting, Scientific

Exhibition. Louisville, KY: “Influence of Estrogen Mimics on ERE-Recognition by Human

Estrogen Receptor- alpha. “

2000 Walser Prize Runner-up, Poster Session. Clinical Ligand Assay Society Annual Meeting. Boston,

MA: “Influence of Estrogen Mimics on ERE Recognition by Human Estrogen Receptor- alpha.”

2011 Elected Fellow, American College of Physicians

2013 Selected as Focus Louisville September 2013 class

2014 Selected as Leadership Louisville “100 Wise Women”

2014 Selected as Louisville Business First “40 under 40”

COMMITTEE ASSIGNMENTS AND ADMINISTRATIVE SERVICES

Beth Israel Deaconess Medical Center/ Harvard Medical School

2003-2005 Fellow Member, Beth Israel Deaconess Cancer Committee

2006-2007 Chief Resident, Department Internal Medicine, Boston, MA

James Graham Brown Cancer Center (JGBCC)/University of Louisville:

2010- Member, University of Louisville Hospital Cancer Committee

2010 - Member, Medical Oncology Operational Leadership Group

2010- Reviewer, JGBCC Clinical Scientific Research Committee

2010- Steering Committee, National Accreditation Program of Breast Centers (NAPBC)

Accreditation

2010 Member, Pharmacy and Technology (P&T) Committee, James G. Brown Cancer Center

2011- Board Member, University Medical Associates

2011-2012 Chair, Psychosocial Distress Subcommittee, UofL Hospital Cancer Committee

2011-2013 Assistant Program Director, Brown Cancer Center Hematology/Oncology Fellowship

2011- Co-Director, Brown Cancer Center Mobile Mammography Research Group

2012- Member, Fellowship Competency Committee

2013 Member, University of Louisville School of Medicine Strategic Planning for Clinical

Enterprise Committee

2013 Founder and Chair, Brown Cancer Center Quality Committee

2013 Member, Brown Cancer Center Program Leadership Committee

2013 Judge, James G. Brown Cancer Center (JGBCC) 11th Annual Retreat Poster Competition 2013 Associate Division Director, Division of Hematology/ Oncology

2013 Director, Breast Cancer Multidisciplinary Clinic

2013 Chair, National Accreditation Program of Breast Cancers (NAPBC) Accreditation

Steering Committee

EDUCATIONAL ACTIVITES

2006-2007 Chief Resident, Internal Medicine, Beth Israel Deaconess Medical Center/Harvard


2010- 2012 Co- Author, Harvard Medical School Online CME Course “Anemia,”

(Mentor: Reed Drews M.D.)

Authored an online case based tutorial on the diagnosis and management of anemia for

Harvard Medical School’s online CME course.


Page 4 of 19

4

2010-2013 Subspecialty Education Coordinator, Hematology/Oncology for Internal Medicine

Residency Program, University of Louisville

Created and managed the UofL Internal Medicine Residency Educational Curriculum

including both inpatient and outpatient activities, as well as didactic topics

2011-2013 Assistant Program Director, Brown Cancer Center Hematology/Oncology Fellowship,


Oversight and mentorship of 9 medical oncology/hematology fellows

2012-2013 Educational Curriculum Coordinator, BCC Hematology/Oncology Fellowship

Program, University of Louisville

Completely revised and updated the educational curriculum of the UofL hematology and

medical oncology fellowship program

Recurring Teaching Conferences/ Beth Israel Deaconess Medical Center/ Harvard Medical School

2005- Lecturer, Tumor Board

One hour long lectures given to 20 hematology-oncology and pathology faculty

members, fellows, residents and students. Topics included but not limited to:

Pharmacogenetics, Fertility Preservation in Cancer patients, Her 2 Neu Positive Breast

Cancer and Racial and Ethnic Disparities in Cancer.

2006-2009 Lecturer, Lymphoma Conference

2006-2007 Lecturer and Moderator, Medical Morbidity and Mortality Conferences

Presented summary of the hospital course of patients who sustained morbidity or

mortality during an inpatient hospitalization. Invited expert faculty discussants and

moderated the one-hour discussion held in front of 80-120 faculty, fellows, residents, and

medical students. One conference per month.

2006-2007 Lecturer and Moderator, Intern and Resident Reports

Prepared case-based reviews of core internal medicine topics for groups of 10-30 medical

residents and 20-40 medical interns and medical students. 1-2 reports were given each

week.

2006-2007 Moderator, Internal Medicine Teaching Attending

Led daily, hour-long educational sessions in various formats (e.g. case-based

presentations, lectures on core internal medicine topics) for groups of internal medicine

residents and medical students regarding the evaluation, diagnosis, and management of

patients admitted to the general internal medicine service. Reviewed written medical

student histories and physicals and observed medical student physical

examinations. Served in this role for three months during the academic year.

30 minute lectures given to 20 hematology-oncology and pathology faculty members,

fellows, residents and students. Topics included but not limited to: Primary Mediastinal

Lymphoma and Rituximab in TTP.

Recurring Teaching Conferences/ Brown Cancer Center Fellowship Conferences

2011 – 2013 Creator and moderator, New Patient Conference

Weekly case based discussions regarding new hematologic and oncologic patients with

fellows and invited expert faculty.


Page 5 of 19

5

2012 – 2013 Creator and moderator, Oncology Plus Conference

Quarterly panel discussions regarding common non-traditional topics regarding oncology

care such as quality, health care disparities, end of life coping and discussion and trainee /

professional burn out.

2012 – current Director, James G. Brown Cancer Center Grand Rounds

Oversee and organize speakers in shared radiation oncology, medical oncology and

hematology weekly conference

Invited Lectureships/ University of Louisville

2010 “Fertility Preservation in the Cancer Patient,” Multimodality Conference

2010 “BRCA 1 and 2 mutations,” Biochemistry lecture and panel discussion

2010 “Biology of Breast Cancer” UofL, Medical Oncology Core Curriculum

2010 “Adjuvant Endocrine therapy”” UofL Medical Oncology, Core Curriculum

2010- Hematology/Oncology Faculty Discussant Internal Medicine Noon Report

2011 “The Mammography Controversy: An Oncologist’s Perspective” UofL OB/GYN

Grand Rounds

2012 “Parp Inhibitors in Breast Cancer” Medical Oncology Journal Club

2011 “Thrombophilia 101” UofL Internal Medicine Residency Didactics

2011 “Breast Cancer” Brown Cancer Center Summer Internship Lecture Series

2011 “Initial Therapy for Advanced Stage Hodgkins Lymphoma” Hematology Conference

“Breast Cancer 101” UofL Internal Medicine Residency Didactics

2012 “Breast Cancer Clinical Overview” UofL Cancer biology graduate course

2012 “Overdiagnosis in Breast Cancer” UofL Department of Medicine Grand Rounds

2012 “Breast Cancer Overview” UofL Medical Oncology fellowship Core Curriculum

2013 “Rethinking DCIS” Brown Cancer Center Grand Rounds

2013 “Breast Cancer Biology” UofL Cancer Biology Course

2013 “Breast Cancer for the Internist” UofL Internal Medicine Residency Didactics

2013 “Breast Cancer” UofL Surgical Oncology Fellow Didactics

2013 “Multidisciplinary Cancer Care” UofL School of Medicine 4th Year Class

2014 “Breast Cancer 101” UofL Internal Medicine Residency Didactics

2014 “Breast Cancer Biology and Future Research Directions” NCI Summer Scholar Lecture

Series

Invited Lectureships/ Regional

2011 “Breast Cancer Update 2011” Owensboro Oncology Conference, Owensboro, KY

2011 “The Mammography Controversy: An Oncologist’s Perspective” Annual Meeting

Kentucky America College of Physicians, Louisville, KY

2012 “Think Pink!” Kentucky Cancer Program, Shepherdsville, KY

2013 “Breast Cancer Treatment and Decisions: 5 Questions to Ask Your Doctor” Women’s

Conference, Bowling Green, KY

2013 “Breast Cancer Risk” Louisville Junior League, Louisville, KY

Clinical and/ or Research Mentorship

Medical Students

2012-2013 Andrew O’Brien, University of Louisville

Residents

2012 Tarsheen Sethi, MD, Internal Medicine, University of Louisville


Page 6 of 19

6

2012- current Laura Barkley, MD, Radiology, University of Louisville

NCI Summer Scholar Mentees

2014- current Sarah Mudra, Wheaton, Chicago IL

Hematology/Oncology Fellows

2012 Blakely Kute, MD University of Louisville

2012- current Mounika Mandadi, MD, University of Louisville

2013- current Tezo Karedan, MD, University of Louisville

CLINICAL ACTIVITES

2009- present Multidisciplinary Outpatient Hematology/Oncology Clinic

Clinical Service: 2 full days per week (Average 50 patients/week, 5 new patients/week) I see approximately 2000 patients a year and approximately 200 new breast cancer

patients each year. My primary clinical focus is the treatment of these women (and some

men) in all stages of breast cancer and survivorship. Additional areas of focus include

hematology (benign and malignant) and breast cancer risk reduction.

Sites: James G. Brown Cancer Center (JGBCC)

2009- current Hematology/Oncology Inpatient Service

Clinical Service: 3 months per year (average 20 patient/day)

Sites: University of Louisville Hospital (ULH,) Norton Downtown Hospital, Jewish

Downtown Hospital and the Louisville VA Hospital

2009- current Clinical Trial Principal Investigator

Clinical Service: PI on average of 6 open trials in breast cancer and hematology, sub I or

co-investigator on additional 15-20 open studies

Sites: ULH, JGBCC

2013- current Associate Division Director, Division of Hematology/Oncology

Clinical Service: Clinical director of medical oncology/ hematology clinical faculty

practice within the Multidisciplinary Clinics at the JGBCC. Revised triage practices and

hematology referral system at the JGBCC (latter in development) and restructured

consult service at Jewish Hospital Downtown.

Sites: ULH, JGBCC, Norton Downtown Hospital, Jewish Hospital Downtown.

2013- current Director, Breast Cancer Multidisciplinary Clinic, JGBCC

Clinical Service: Director of Kentucky’s first accredited breast program by the National

Accreditation Program of Breast Centers (NAPBC.) Responsible for maintenance of

accreditation and oversight of the multidisciplinary clinic which includes medical


Page 7 of 19

7

oncology, radiation oncology, surgical oncology, genetics, mammographic radiology, and

pathology.

Sites: JGBCC

RESEARCH FUNDING/ ACTIVITES

Past Support: Mentored Research

1. Resident Work Hours Implications on Error

Evaluated resident and attending perspectives on the ACGME’s 80 hour work week regulations

and resident error

Mentor: Anjala Tess M.D. Department of Medicine, Beth BIDMC, Boston, MA

2005

2. Comparison of local and central renal cell pathology interpretations

Evaluated concordance of local pathology interpretation (LR) with central pathology review (CR)

in primary tumor specimens from patients with renal cancer (RCC).

Mentor: Michael B. Atkins, M.D., Director Biologics Program, Department of Oncology, BIDMC,

Boston, MA

2004-2005

3. Quantitative Analysis of Synthetic and Phytoestrogens on ER-alpha Activity

Laboratory based research aimed at developing a method to quantitatively analyze estrogen

mimics’ influence on recombinant human estrogen receptor alpha activity.

Mentor: James L.Wittliff, Ph.D., Director Hormone Receptor Laboratory, James Brown Cancer

Center, University of Louisville, Louisville, KY

1999

Current Support: Investigator Initiated Research

1. Mobile Mammography Project 1: The impact of mobile mammography on trends and disparities in

the diagnosis of breast cancer at a comprehensive cancer center in an underserved state.

Analysis of demographic, racial and ethnic trends in mobile mammography utilization in Jefferson

County, KY

Role Co- PI

Period of Support 2011 - ongoing

Award Intramural funding

2. Survey of the Quality of Life of Patients with Breast Cancer Treated with Chemotherapy

in the Neoadjuvant vs. Adjuvant Setting


Page 8 of 19

8

Comparison of health related quality of life between breast cancer chemotherapy patients treated

before vs. after surgical treatment.

Role PI

Period of Support 2014-2016

Award $39,858.00

3. Estimating the Adherence of Oral Anti-estrogens with a Bubble Pack

Investigator initiated Phase II Feasibility study investigating altering breast cancer therapy pill

packaging in an effort to improve compliance

Role PI

Period of Support 2012 to current or 120 patients

Award $86,980.00

4. Mobile Mammography Project 2: Development of a clinical database of women diagnosed through

the Mobile Mammography Van of the Kentucky Cancer Program

Estimation of risk factors and biological features of breast cancer diagnosed through the mobile

mammography van in Jefferson County, KY

Role Co- Director Research Group, Project PI

Period of Support 2014-

Award Intramural Funding

Under development/Pending Support: Investigator Initiated Research

1. Mobile Mammography at the JGBCC: Reviewing and Implementing Hispanic Outreach

Evaluation of mobile mammography by the currently most vulnerable ethnic group for repeat van

utilization in Jefferson County, KY

Role Co- Investigator

Award pending

Past Support: Clinical Research

1. NSABP Cooperative Group Trial Support

Title: Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast

Cancer.

Role: University of Louisville site Principal Investigator (from 2009-20012)

Period of Support: 1999-2012

Total Award: $160,738.29

Direct Amount $127,570.07


Page 9 of 19

9

2. Novartis Pharmaceuticals Trial Support

Title: A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in

combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-

expressing locally advanced or metastatic breast cancer

Role: Sub investigator (PI Jain, D)

Period of support 2010-2011

Total award $7,834.00

Direct amount $6,217.46

3. Genetech Pharmaceutical Trial Support

Title MARIANNE A randomized, 3 arm, multicenter, phase III study to evaluate the efficacy

and the safety of T-DM1 combined with Pertuzumab or T-DM1 combined with

Pertuzumab-Placebo, versus the combination of Herceptin plus taxane, as 1st line

treatment in HER2 positive progressive or recurrent locally advanced or metastatic

breast cancer

Role Sub investigator (PI Jain, D)

Period of support 2010-2011



4. ISIS Trial Support

Title A Phase 1b/2 Study of Carboplatin-Paclitaxel, with or without ISIS 183750 (an

eIF4E Inhibitor), in Patients with Stage IV Non-Small Cell Lung Cancer

Role Sub investigator (PI Kloecker, G)

Period of support 2011 -2014



5. SuperGen Trial Support

Title A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination with

Platinum- Etoposide Chemotherapy in Small Cell Lung Cancer Subjects who have not

Responded to Standard Treatment or Relapsed After Standard Treatment

Role Sub Investigator (PI Kloecker, G)

Period of Support 2011-2013

Total Award $42,516.00


Current Support: Clinical Research


Page 10 of 19

10

1. NSABP Cooperative Group Trial Support

Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy

Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of

Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to

Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk

Node-Negative HER2-Low Invasive Breast Cancer

Role: University of Louisville site Principal Investigator

Period of Support: 2011- ongoing



2. Galena Trial Support

Title: PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer

with Low to Intermediate HER2 Expression with NeuVax(tm) Treatment

Role: University of Louisville site Principal Investigator

Period of Support: 2012- ongoing



3. Genetech Pharmaceutical Trial Support

Title An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the

Efficacy and Safety of Bendamustine Compared with Bendamustine + Ro5072759

(Ga101) in Patients with Rituximab-Refractory, Indolent Non-Hodgkin’s

Lymphoma

Role University of Louisville site Principal Investigator

Period of Support 2013- ongoing



4. ECOG Cooperative Group Trial Support

Title E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the

Intact Primary Tumor in Patients with Metastatic Breast Cancer

Role University of Louisville site Principal Investigator

Period of Support 2013- ongoing

Total Award n/a

5. NSABP Cooperative Group Support

Title NSABP B-38 06.0075 - A Phase III, Adjuvant Trial Comparing Three Chemotherapy

Regimens in Women with Node Positive Breast Cancer: Docetaxel/ Doxorubicin/

Cyclophosphamide (TAC); Dose Dense (DD) Doxorubicin/Cyclophosphamide followed by

DD Paclitaxel (DD AC —> P); DD AC followed by DD Paclitaxel Plus Gemcitabine (DD

AC —> PG) Role Sub Investigator (PI Jain, D)


Page 11 of 19

11


Total Award $8000

Direct Amount $6349.21

6. Cooperative Group Support

Title PACCT-1 06.0362 - Program for the Assessment of Clinical Cancer Tests: Trial Assigning

Individualized Options for Treatment: the TailorRx Trial

Role: Sub Investigator (PI Jain, D)

Period of Support: 2006-




Title B-42 Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared

to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an

Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free

Survival in Postmenopausal Women with Hormonal Receptor Positive Breast Cancer

Role: Sub Investigator (PI Jain, D)


Total Award n/a

Direct Amount n/a


Title B-40 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and

Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of

Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or

without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of

High Likelihood for pCR with Each of the Regimens

Role Sub Investigator (PI Jain, D)




9. ACOSOG Cooperative Group Trial Support

Title Z 1041: A Randomized Phase III trial comparing Neoadjuvant Regimen of FEC-75 followed

by Paclitaxel Plus Trastuzumab with a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab

Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 Positive Operable Breast

Cancer






Page 12 of 19

12

10. Cooperative Group Trial Support

Title ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study; A

Randomized, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib,

Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2

Positive Primary Breast Cancer





11. RTOG Cooperative Group Trial Support Title RTOG-0413 NSABP B-39 09.0287 - (prev. 06.0217) A randomized Phase III study of

Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for

Women with stage 0, I, or II Breast Cancer

Role Sub Investigator (PI Woo, S)




12. Novartis Pharmaceutical Clinical Trial Support

Title A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with

Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive,

Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or

Anastrozole.





13. Imclone Clinical Trial Support

Title An Open-label, Multicenter, Randomized, Phase 2 Study of a recombinant Human Anti-

VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based

Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatment of

Patients with Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)



Total Award $43,631


14. Eisai Pharmaceutical Clinical Trial Support


Page 13 of 19

13

Title ELEVATE- A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy

and Safety of Eribulin with Treatment of Physician’s Choice in Subjects with Advanced Non-

Small Cell Lung Cancer.

Role: Sub Investigator (PI Kloecker, G)




15. Pfizer Pharmaceutical Clinical Trial Support

Title ARCHER 1009 -A Randomized Double Blind Phase 3 Efficacy and Safety Study Of PF-

00299804(Dacomitinib) Versus Erlotinib for the Treatment Of Advanced Non Small Cell Lung

Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy





16. Boehringer Pharmaceutical Clinical Trial Support

Title LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients

with advanced squamous cell carcinoma of the lung a second-line therapy following first-line

platinum-based chemotherapy





17. NSABP Cooperative Group Clinical Trial Support

Title B-49 A Phase III clinical Trial Comparing the Combination of Docetaxel Plus

Cyclophosphamide to Anthracycline Based Chemotherapy Regimens for Women with Node

Positive or High Risk Node Negative, Her 2 Negative Breast Cancer





18. Lilly Pharmaceutical Support

Title A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy

Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV

Squamous Non-Small Cell Lung Cancer (NSCLC)






Page 14 of 19

14

19. James Graham Brown Cancer Center

Title Protocol for the Cancer Database and Specimen Repository (CDSR) at the James Graham

Brown Cancer Center (Previous Lung Repository <LDSR>)



Total Award intramural

Direct Amount intramural


Title A Phase II Trial of Extended Interval Port Flushes





21. SWOG Cooperative Group Clinical Trial Support

Title S1007 - A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/-

Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-

Negative Breast Cancer with Recurrence Score (RS) of 25 or Less





22. Transgene Pharmaceutical Clinical Trial Support

Title A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line

therapy with or without TG4010 immunotherapy product in patients with stage IV non-small

cell lung cancer (NSCLC)





23. Amgen Pharmaceutical Clinical Trial Support

Title Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen

or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and

Pegfilgrastim



Total Award n/a

Direct Amount n/a


Page 15 of 19

15

24. Pfizer Pharmaceutical Clinical Trial Support

Title A Randomized, Multicenter, Double-Blind Phase 3 Study of Pd-0332991 (Oral Cdk 4/6

Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal

Women with Er (+), Her2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti-

Cancer Treatment for Advanced Disease


Period of Support 2013

Total Award $8473.00

Direct Amount $6724.60


Title PACE 13.0338 - PACE of Breast Cancer (Predicting Adverse Cardiac Events of BC)

Role Sub Investigator (PI Lenneman, C)




26. Amgen Pharmaceutical Clinical Trial Support

Title A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and

Efficacy of Darbepoetin Alfa Administered at 500 μg Once-Every-3-Weeks in Anemic Subjects

With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy



Total Award n/a

Direct Amount n/a

27. ACT Advanced Cancer Therapeutics Clinical Trial Support

Title A Phase 1, Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients

with Advanced Solid Malignancies

Role Sub Investigator (PI Redman, R)


Total Award n/a

Direct Amount n/a

PATENTS

None

EDITORIAL WORK


Page 16 of 19

16

2014 Ad Hoc Journal of Oncology Practice (JOP)

ABSTRACTS AND PRESENTATIONS

ORAL PRESENTATIONS

1. Mizuguchi S, Barkley L, Roland L, Rai SN, Pan J, Riley EC Mobile Mammography

Utilization Trends and Disparities Over a Decade at a Comprehensive Urban Cancer

Center. Oral presentation, Radiological Society of North America December 2013.

POSTERS

1. Carloss EA, Vago B, & Wittliff JL. Influence of Estrogen Mimics on ERE-

Recognition by Human Estrogen Receptor-a. 2000 Clinical Ligand Assay Society

Annual Meeting. Boston, MA.

2. Carloss E, Regan M, Upton M, Youmans A, McDermott D, Polivy A, , Atkins A.

Concordance of local pathology interpretation (LR) with central pathology review

(CR) in primary tumor specimens from patients with renal cancer (RCC). Poster

Session: Genitourinary Cancer, 2004 ASCO Annual Meeting.

3. Dragun AE, Pan J, Riley E, Kruse B, Wilson M, Rai S, Jain D. Increasing use of

mastectomy with immediate reconstruction and contralateral prophylactic

mastectomy in breast conservation candidates: A 14-year report from a

comprehensive cancer center. Poster Session Breast Cancer - Triple-

negative/Cytotoxics/Local Therapy. 2011 ASCO Annual Meeting. J Clin Oncol 29:

2011 (suppl; abstr 1104) Presenter

4. Barry PN, Riley EC, Pan J, Crew JB, Le K, Jain D, Kruse B, Quillo AR, Rai S,

Dragun AE. Delay of Adjuvant Chemotherapy after Elective Mastectomy and

Immediate Reconstruction in Breast Conservation Candidates: A Matched – Pair

Analysis. Poster Session. CTRC-AACR San Antonio Breast Cancer Symposium

2011. Cancer Res; 71 (24 suppl.) Dec 2011

5. Milam MR, Cummings S; Wilcox L; Riley EC; Soliman PT; Myers JA . Risk

Factors for Uterine Cancer in Breast Cancer Survivors: An Army of Women Study.

61st Annual Clinical Meeting The American College of Obstetricians and

Gynecologists. New Orleans, LA. May 2013.

6. Riley EC, Roland LC, Barkley L, Mandadi M, Rai SN, Pan J and Mizuguchi SG

Insurance Status to predict repeat Mobile mammography Utilization: 10 year

analysis of a Comprehensive Urban Cancer Center Poster Session CTRC- AACR

San Antonio Breast Cancer Symposium December 2013.

7. Riley EC, Jain D, Kantardzic B, Wu X, Rai, SN Demographic Trends in Clinical

Trial Withdrawal Rate within the Bubble Study. Poster Session CTRC- AACR San

Antonio Breast Cancer Symposium December 2013

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=102


Page 17 of 19

17

8. Riley EC, Roland LC, Barkley, Rai SN, Pan J and Mizuguchi SG Impact of

Location to Repeat Mobile Mammography Utilization Trends: 10 year analysis of a

Comprehensive Urban Cancer Center. Poster Session ASCO Annual Meeting 2014.

9. Riley EC, Dragun A, McMasters K, Scoggins C, Quillo A, Rai S, Wu X, Jain D

Compliance with oral antiestrogens utilizing a bubble pack. Poster Session ASCO

Breast Symposium Sept 2014.

10. Riley EC, Roland LC, Barkley, Rai SN, Pan J and Mizuguchi SG Uninsured

utilization of the mobile mammography: 10-year analysis. Poster Session ASCO

Breast Symposium Sept 2014.

11. Dragun A, Riley E, Quillo A, Barry P, Hunter A, Rajeur A, Roberts T, Rai S, Pan J,

Jain D, Scoggins C, McMasters K A phase II trial of once-weekly hypofractionated

breast irradiation (WHBI): Interim analysis of cosmetic outcome and quality of life.

Poster Session ASCO Breast Symposium Sept 2014.

Submitted Abstracts/Pending

1. Riley EC, Roland LC, Barkley, Rai SN, Pan J and Mizuguchi SG Multivariable Analysis of Repeat

Utilization of Mobile Mammography Units: 10 year analysis of a Comprehensive Cancer Center

Submitted June 2014 to San Antonio Breast Cancer Symposium 2014

2. Riley EC, Dragun A, McMasters K, Quillo A, Scoggins C , Wu X, Rai S, Jain, D. Demographic trends

in clinical trial withdrawal rate within the bubble study: Updated analysis. Submitted June 2014 to

ASCO Quality Symposium 2014.

PUBLICATIONS

PEER REVIEWED

1. Carloss H, Huang B, Cohen A, Carloss E, Wyatt S, Tucker T. The Impact of Number of Lymph

Nodes Removed on 5 Year Survival in Stage II Colon and Rectal Cancer. J. KY Med Assoc. 2004

Aug; 102(8):345-7.

2. Sharma V, Brannon M, Carloss E. Refractoriness to Oral Iron Replacement in Patients with Iron

Deficient Anemia Taking Omeprazole. South Med J. 2004 Sep;97(9): 887-9.

3. Huang, B, Carloss H, Wyatt, S, Riley E. Hormone Replacement Therapy and Survival of Lung cancer

in Postmenopausal Women in a Rural Population. Cancer 2009; 115(18): 4167-4175.

4. Riley, E, Drews, R " Anemia" Harvard University Online CME Curriculum Program 2010

http://cmeonline.med.harvard.edu/course_descriptions.asp?Course_id=114&group_name=Medicine

5. Riley, E, Carloss, H Dramatic Response to Panitumumab and Bevacizumab in Metastatic Gallbladder

Carcinoma The Oncologist 2011; 16: e1-e2; doi:10.1634/theoncologist.2008-0196

http://theoncologist.alphamedpress.org/cgi/content/full/16/5/e1

http://theoncologist.alphamedpress.org/cgi/content/full/16/5/e1


Page 18 of 19

18

6. Riley E, Moy, B Ethical Challenges: Caring for the Underinsured Geographically Disadvantaged

Patient. J Oncol Prac 8:215-218, 2012

7. Dragun, A, Quillo, A, Riley, E et al, A Phase 2 Trial of Once-Weekly Hypofractionated Breast

Irradiation: First Report of Acute Toxicity, Feasibility and Patient Satisfaction Int J Radiat Oncol Biol

Phys. 2013 Mar 1;85(3):e123-8. doi: 10.1016/j.ijrobp.2012.10.021. Epub 2012 Nov 27.

8. Dragun AE, Pan J, Riley EC, Kruse B, Wilson MR, Rai S, Jain D. Increasing the use of elective

mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14 -

year report from a comprehensive cancer center. Am J Clin Oncol. 2013 Aug;36(4):375-80. doi:

10.1097/COC.0b013e318248da47

9. Barry PN, Riley EC, Pan J, Crew JB, Lee K, Jain D, Kruse B, Quillo AR, Rai S, Dragun AE. Delay of

Adjuvant Chemotherapy After Elective Mastectomy and immediate reconstruction in breast-

conservation candidates: a matched-pair analysis. Am J Clin Oncol. 2013 Mar 4. [Epub ahead of print]

PubMed PMID: 23466579

10. Boone S, Baumgartner K, Baumgartner R, Cooner A, Pinkston C, Rai S, Riley E, Hines L, Giuliano A,

John E, Stern M, Torres-Mejia G, Wolff R, Slattery M. Associates between CYP19A1

polymorphisms, Native American Ancestry, and breast cancer risk and mortality: the Breast Cancer

Health Disparities Study. Cancer Causes and Control, accepted July 2014 pending publication.

Under Review/Submitted

11. Mizuguchi S, Barkley L, Rai S, Pan J, Roland L, Crawford S, Riley, E Mobile Mammography and

Race: Utilization Trends Over a Decade at a Comprehensive Urban Cancer Center. Under Review

JOP submitted March 2014

12. Torres D, Myers A, Cummings S, Wilcox L, Riley E, Soliman P, Milam, M Risk Factors for the

Development of Uterine Cancer in Breast Cancer Survivors: An Army of Women Study. Submitted

Annuals of Oncology, April 2014.

NON PEER REVIEWED

Book Chapters

1. Sethi, T, Riley, E “Antiphospholipid Antibody Syndrome” 5 Minute Clinical Consult, 2014

Edition

2. Sethi, T, Riley, E “Antiphospholipid Antibody Syndrome” 5 Minute Clinical Consult, 2015

Edition


Page 19 of 19

19

Abstracts

1. Vinayek N, Kloecker G, Riley, B Multiple Myeloma with

Secretory and Non-Secretory Biclonal Gammopathy Blood (ASH Annual Meeting

Abstracts), Nov 2011; 118: 5092

Documents

CURRICULUM VITAE Elizabeth Carloss Riley M.D., FACP James